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There  is  a  close  morphological and  biochemical relationship between leukemia 
and sarcoma viruses of  the oncorna type. There is a functional relationship as well, 
since the leukemia viruses act as helpers, required for  the production of infectious 
sarcoma virus. The genetic information contributed by the sarcoma virus is required, 
on the other hand, for the induction of solid tumors and the transformation of mono- 
layer cultures. One remarkable characteristic of the murine sarcoma virus is its ability 
to transgress species barriers. The murine leukemia viruses are essentially confined to 
their host species and many of them have exacting requirements within the species: 
their oncogenic effect  is strongly dependent on host genetic factors. The murine sar- 
coma viruses (MSV) 1 have not been distinguishable from the murine leukemia viruses 
(MuLV) by such characteristics as size (1), kinetics of inactivation (1, 2), morphology 
(3),  or  antigenic specificity  (4-7).  As  a  rule,  however,  the  immunological studies 
have been performed with MSV-induced tumors or with in vitro transformed cells 
that released both MSV and MuLV. 
One such study (7) has been carried out with the specific purpose of distinguishing 
between MSV- and MuLV-associated antigens on MSV-induced sarcoma cells. Exten- 
sive  cross-absorption of  anti-Moloney leukemia virus  (MLV)  and  anti-MSV sera 
with leukemia and sarcoma cells did not give any evidence of antigens specifically 
associated with MSV-transformed cells that were  not also present on MLV-induced 
leukemia cells. Furthermore, tolerance to MLV was not broken by MSV inoculation. 
No virus-specific antigen was detected on the surface of MSV-induced nonproducer 
hamster cells. 
* These investigations were conducted under Contract  No.  NIH-NCI-E-69-2005 within 
the Special Virus Cancer Program  of the National Cancer Institute, National Institutes of 
Health,  U.S. Public  Health Service; the  Swedish Cancer  Society;  and  the  Jane  Coffin 
Cbilds Memorial Fund for Medical Research. 
:~ The work reported in this paper was undertaken during the tenure of a Research Training 
Fellowship awarded by the International  Agency for Research on Cancer. 
§ Recipient of NIH Training Grant No. 5 TO1  G M01924-03, Clinical Investigators  in 
Academic Surgery, Dept. of Surgery, University of Alabama in Birmingham Medical Center. 
1  Abbreviations used in this paper: D56-M, MLV superinfected D56 cells; MLV, Moloney 
leukemia virus;  MSV, murine sarcoma virus;  MuLV,  murine leukemia viruses; NP, non- 
producing;  S+L--, sarcoma positive,  leukemia negative;  TATA, tumor-assoclated trans- 
plantation antigens; TSTA, tumor-specific transplantation antigens. 
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Recently,  some  MSV-transformed  mouse  sarcoma  lines  have  been  isolated  by 
appropriate selection procedures that do not produce any helper MuLV nor do they 
make any MSV (8, 9). Two different types of MSV-transformed 3T3 cells have been 
described  within this  category.  One is a  true  nonproducer line  (10),  isolated  from 
BALB/3T3 monolayers infected with the Moloney isolate of MSV. The other isolate, 
designated  S +L-  (sarcoma positive, leukemia negative) was  selected from  among 
semisolid agar  colonies of  MSV-transformed  Swiss/3T3  cells  (9).  Although  S+L- 
cells do not release any infectious virus, they produce a  small number of C-type par- 
ticles that are indistinguishable from infectious murine leukemia-sarcoma virus (ll). 
It was suggested that these particles represent a form of MSV deficient in one or more 
of the viral components required for infectivity. 
In  view  of  the  fact  that  the  previous  antigenic  characterization  of  MSV 
(MuLV)-transformed  cells  was  carried  out  with  target  cells  that  produced 
large quantities of MuLV,  the exclusive demonstration of MuLV-type but no 
MSV-specific surface antigens appeared questionable. Conceivably, the strong 
MuLV-determined surface antigens may have overshadowed any MSV-specific 
components. The question was  therefore reexamined by the surface  antigenic 
characterization of the S+L--  cells reported in the present study. 
Materials  and Methods 
Cells.--The  following  cell lines were  used:  (a)  normal 3T3 cells from NIH/Swiss mice; 
(b) S+L--  cells isolated from semisolid  agar colonies of MSV-transformed 3T3 cells, twice 
cloned by plating at limiting dilutions in microplates (11); (c) D56 cells, a mixture of S +L-- 
cells and normal cells. It has been shown that routine leukemia viruses induce plaque forma- 
tion on D56 monolayers and a sensitive titration method has been developed  for •uLV  on 
this basis (12) ; (d) MLV superinfected D56 cells  (D56-M).  Superinfection was performed as 
described by Bassinet al. (12). One culture which had 12 plaques on the 5th day was kept in 
passage.  Antigenic conversion, demonstrated by a positive reaction with anti-MLV sera in 
the mixed hemadsorption test (13), occurred  from the 3rd passage  onwards; (e) Ha2 line, an 
MSV-induced tumor of  the  CBA mouse strain grown in tissue culture. It produces both 
MSV and MLV (7). Cell lines (a),  (b), and (c) have been provided through the courtesy of 
Dr. R. H. Bassin, National Cancer Institute, Bethesda, Md. 
The medium used for growth and maintenance of all cells was McCoy's 5a  (modified) 
supplemented with  10%  fetal  bovine serum.  For  the lymphocyte cytotoxicity assay and 
mixed hemadsorption the ceils were grown in Eagle's minimal essential medium (Earle's salts) 
supplemented with 10% fetal bovine serum  (inactivated for 60 rain at  56°C).  They were 
seeded  in the wells  of Microtest plates  (Falcon Plastics, Div. B-D Laboratories, Inc., Los 
Angeles, Calif.) and incubated 18-24 hr at 37°C in 5% CO2 before testing. 
Virus.--A  50% homogenate of the YAC, a  Moloney virus-induced lymphoma of strain 
A/Sn origin, served as the source of Moloney virus (MLV)  (13). MSV was derived from the 
224th passage in BALB/c mice, kindly provided by J. B. Moloney, National Cancer Institute, 
Bethesda, Md..  : 
Sera.--Anti-D56  serum was produced by inoculating five C57BL mice with D56 cells in 
doses ranging from 7.0 X  104 to 1.9 ;K 106 cells twice weekly over a period of 4 months. Serum 
was collected and pooled during the last month of immunization. 
Anti-MLV serum:  Collected  from 30 (A X  C571eaden)F1 hybrid mice 90-180 days after a 
single inoculation of a 10% homogenate, prepared from YAC. 
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irradiated with 10,000 R  and inoculated into six C57BL mice. Sera were collected from three 
tumor-free mice 2  months later, pooled,  and  designated pool I.  The sera  of three tumor- 
bearing mice were designated as pool II. In another series, MSV was inoculated into a group 
of six adult C57BL mice; all developed tumors that regressed within 1 month. Serum pool III 
was collected from these mice 1 month after complete regression. 
Absorption of C57BL Anti-D56  Serum with Normal 3T3 Cells.I4 X  106 normal 3T3 cells 
were mixed with 0.3 ml of undiluted serum and incubated for 30 min at 37°C, followed by 30 
rain at 4°C. The cells were removed by one centrifugation at 1500 g. The entire absorption 
procedure was repeated twice. A final centrifugation at 5000 g concluded the procedure and 
the serum was frozen and stored at --20°C. 
Mixed Hemadsorption  Test.--Cells were  seeded  in  the wells  of  Falcon  microtest plates 
(Falcon Plastics, Div. B-D Laboratories, Inc.)  and incubated for 18-40 hr at 37°C  in  5% 
CO2.  A  micromodification of the mixed hemadsorption technique was  used  (14).  Veronal- 
buffered saline containing 5% gelatin was used as diluent and washing fluid. The indicator 
cells were prepared as previously described  (15). Normal mouse serum and all antisera were 
tested at reciprocal dilutions of 3, 10, 30, 100, 300, and 1000. Six wells with buffer alone were 
included in each mierotiter plate. The test was performed as described previously (15). In all 
experimonts  two  different  combinations  of  amboceptor  and  anti-mouse  gamma  globulin 
serum were used:  1:1200,  1:50 and  1:800,  1:30, respectively. The strength of the reaction 
was evaluated under the microscope and graded as follows: +  +  +  +, all target cells covered 
by a heavy layer of sensitized sheep erythrocytes; +  +  +, almost all target cells show attached 
erythrocytes, most of them with complete rosettes; ++,  50-100% of the cells show three or 
more attached erythrocytes, with some complete rosettes; +, less than 50% of the cells have 
two or more attached erythrocytes; --, no attached erythrocytes. 
Lymphocyte Cytotoxicity Assay.--The lymphocyte cytotoxicity assay was  carried  out  by 
the method of Takasugi and Klein (16). Lymphocytes were harvested from peripheral lymph 
nodes  of  (a) BALB/c  mice  24  days  after  MSV  infection of  1-month old  animals,  at  the 
time of tumor regression; (b) Fischer rats, 49 days after MSV infection of 3-day old animals, 
either at the time of tumor regression (regressor rat) or from a tumor-bearing rat (progressor) ; 
and  (c)  control animals of the same age. The nodes were teased apart in ice-cold medium, 
mixed thoroughly to break clumps, and passed through a nylon mesh filter. The lymphocytes 
were washed in serum-free medium by three cycles of centrifugation, finally resuspended in 
minimal essential medium containing 10% fetal bovine serum, and were applied to the target 
cells in three concentrations. The relative percentage of surviving target cells was calculated 
from the mean of the six replicates receiving immune lymphocytes, compared with the control 
wells with the same ratio of normal lymphocytes and target cells. 
RESULTS 
Serology.--Two  different  approaches were  used  to search for possible MSV- 
specific  surface  antigens,  as  shown in Table  I.  In one  approach,  isoantibody- 
free sera were obtained by immunization  with  MLV  of syngeneic origin or by 
allowing primary,  autologous  MSV  sarcomas  to  regress.  The  sera were  subse- 
quently tested for reactivity against MSV-induced  sarcoma cells. In the second 
approach,  alloantisera  obtained  by  immunizing  C57BL  mice  with  D56  cells 
were  absorbed  with  the  corresponding  nontransformed  3T3  cells.  After  all 
activity against 3T3 had been removed,  the sera were tested against D56 cells. 
None of the two MSV-transformed,  MuLV-free cell lines (S+L-  and D56) 
gave  any reaction  with  the anti-MLV  and  anti-MSV  sera.  Both  types  of sera 
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TABLE  I 
Reactivity of MSV-Transformed Cell Lines in Mixed Hemadsorption Test 
Reciprocal dilution of 
antiserum 
Cell lines 
Normal 3T3  S +  L--  D56  D56-M  Ha2 
No.  of tests  6  6  10  8  2 
MLV* 
3  --  --  --  ++  + 
10  -  -  -  ++  + 
30  --  --  --  +  -- 
100  ..... 
MSV I* 
3  --  --  --  ++  + 
10  -  -  -  ++  + 
30  -  -  -  +  + 
100  ..... 
MSV  II$ 
3  --  --  --  ++  + 
10  --  --  --  +++  ++ 
3O  --  --  --  ++  ++ 
100  --  --  --  +  + 
300  ....  + 
MSV  III§ 
3  -  -  -  +++  + 
10  -  -  -  +++  ++ 
30  -  -  -  ++  + 
IO0  -  -  -  ++  + 
300  -  -  -  +  - 
loo0  ..... 
C57BL  anti-D56 
3  +++  ++  +++ 
10  ++  ++  +++ 
30  ++  ++  ++ 
100  +  +  +  + 
3OO  +  -  + 
10OO  --  --  + 
C57BL anti-D56 absorbed 
3T3 
10  --  --  -- 
30  --  --  -- 
Evaluation  of  the  strength  of  the  mixed  hemadsorption  reaction:  +++,  almost  all 
target  cells  show  attached  erythrocytes,  most  in  complete  rosettes;  ++,  50-100%  of  the 
cells  show three  or more attached  erythrocytes,  some complete  rosettes;  +,  less than  50% 
of  the  cells  have  two  or  more  erythrocytes  sticking  to  their  surface;  --,  no  erythrocytes. 
Appropriate dilutions of the normal mouse serum and buffer alone did not give any reaction. 
* Serum collected  from mice immunized with irradiated  tumor cells. 
J~ Serum collected  from tumor-bearing mice. 
§ Serum collected  from postrejection  hosts. 348  CELLS  TRANSFORMED  BY  MURINE  SARCOMA  VIRUS 
producing Ha2. It is of interest to note that the sera of mice that rejected their 
own primary  MSV-induced  tumors gave  the highest  antibody  titers  (1:300) 
against the D56-M cells. The serum of tumor-bearing animals (MSV II) gave a 
somewhat  lower  titer  (1:100).  Animals  pretreated  with  irradiated  leukemia 
(MLV)  or sarcoma (MSV I) cells titered  1:30  against D56-M  cells. 
Normal 3T3, S-f-L--,  and D56 cells were all highly reactive with the C57BL 
anti-D56  serum.  This  was,  however, due  to  antibodies  against  the histocom- 
TABLE  II 
Sensitivity of D56, D56-M, Ha2, and A78  Cells to  the  Cytotoy& Action of 
Lymphocytes .from MSV-Infected  Animals 
Donor of 
lymph 
node 
cells* 
Cells 
Control 
Regressor  Ha2  119  4-  25 
mouse  D56  132  4-  27 
D56 M  167  4-  42 
Regressor  A78  132  4-  11 
rat  Ha2  312  4-  18 
D56  162  ±  19 
Progres-  A78  191  4-  23 
sor rat  Ila2  200  4-  7 
D56  68  4-  9 
I.ymph  node  cell:  target  cell  ratio 
100:1  25:1 
No.  of  cells/' 
well 4- SD 
MSV 
infected 
50:1 
No.  of cells/ 
well 4-  SD 
Control  MSV  infected 
41  21  371 
153  40  116 
98  30  59' 
75  8  57 ~ 
221  6  70  ~ 
329  36  .)03 
121  15  63 ~ 
131  ±  11  66 ~ 
68  4-  12  100 
180  4-  36  75  4-  35  5l 1 
86  -4-  39  144  -4-  41  168 
164  ±  57  145  4-  32  89 
186  4-  t4  144  4-  21  773 
380  4-  17  275  4-  12  72 e  i 
172  4-  18  180  4-  31  104  I 
144  4-  19  127  4-  10  88 
205  ±  9  151  4-  7  73 
78  4-  32  129  4-  12  165 
No.  of cells/ 
well 4-  sn 
% 
Control  MSV  infected 
137  4-  55  80  -4-  30 
I31  4-  27  172  4-  24 
150  :h  42  160  -4-  69 
152  4-  17  175  4-  23 
327  4-  20  299  4-  15 
197  ±  36  253  4-  30 
141  4-  5  99  4-  21 
193  ±  2l  208  4-  11 
61  4-  14  137  ±  6 
,582 
136 
107 
115 
91 
122 
76  ~ 
118 
225 
P  values:  1 <  0.0005,  2  <  0.005,  3  <  0.025. 
* Regressor mouse:  lymph node cells were harvested  from BALB/c  mice 24 days after MSV infection  at the 
time of tumor regression.  Rat:  lymph node cells were harvested  from Fischer  rats  49 days after MSV infection, 
either at the time of tumor regression  (regressor) or from a  tumor-bearing  rat  (progressor). 
:~ Relative  percentage  of surviving  target  cells  was  calculated  as  follows: 
Mean No.  of target  cells  in six replicate  wells  receiving  immune  lymphocytes 
X  100. 
Mean No.  of target  cells  in six replicate  wells  receiving  normal  lymphocytes 
patibility  antigens of D56  cells recognized by  the C57BL  mice, since it could 
be removed by absorption with normal 3T3 cells. 
These  experiments  suggest  that  Sq-L--  cells,  although  they  contain  the 
MSV genome, do not differ from the original 3T3  cells in their antigenic char- 
acteristics. 
Cell-Mediated  Cyloloxicity.  Table II shows the effect of mouse or rat lympho- 
cytes  on D56  and Ha2  cells,  respectively.  Immune lymph node cells of both 
kinds reduced  the number of Ha2  cells but  not the number of D56  cells per 
well.  Ha2  cells  were killed  by  mouse lymph  node  cells most notably  on  the 
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results of the mixed hemadsorption test, where a new, virus-associated antigen 
could be detected on D56 cells after superinfection with MLV, immune lympho- 
cytes killed the D56-M cells,  while the same lymphocytes did not affect D56 
cells.  Rat lymph node cells harvested from tumor-bearing rats  (progressor) or 
from rats  after tumor regression  (regressor) were  equally cytotoxic for Ha2 
cells.  A similar cytotoxic effect could be demonstrated on A78 cells (an MLV- 
MSV producer cell line of Wistar rat origin). When the same lymphocytes were 
tested against D56 cells they did not reduce the target cell number, however, 
but  rather stimulated  target  cell  growth.  Control lymphocytes produced no 
cytotoxicity against either line. 
DISCUSSION 
The present study thus confirms the previous evidence, obtained with double 
producing cells, showing that there is no evidence for any MSV-specific surface 
antigen. No antibodies directed against S+L-  or D56 cells could be detected 
in the sera of mice immunized with MSV or with MSV-induced  tumor cells 
and immune lymphocytes also failed to give any evidence of MSV-specific cyto- 
toxicity.  It  is  therefore difficult  to  avoid  the  conclusion  that,  unlike  other 
oncogenic and transforming viruses, MSV does not induce the appearance of 
new surface antigens in the transformant target cell, known to carry the viral 
genome. 
An  analogous conclusion was obtained by Stephenson and Aaronson  (17), 
using a different approach. Nonproducing (NP) MSV-transformed BALB/3T3 
cells were found  to  grow  equally well  in  virus-immunized and  control  mice 
and  thus lacked a  tumor-specific transplantation  antigen.  In contrast to the 
S+L-- cells used in the present study, NP cells were negative for virus particles 
by electron microscopy or by the uridine-aH incorporation method. In addition 
to the production of noninfectious particles (10), as already mentioned, S+L-- 
cells also differ from NP  cells by containing at least  some of the MuLV gs 
antigens  (18)  that  are  absent from NP  cells  (10).  Superinfection of S+L- 
cells with MuLV induces plaque-like lesions, furthermore, while nonproducer 
cells do not show any apparent morphological changes. It therefore seems that 
S+L-  cells  express more virally associated  genetic  information than  non- 
producer cells.  While  sufficient for the production of noninfectious and pre- 
sumably incomplete virus particles and the synthesis of gs  antigens,  this in- 
formation  apparently  does  not  include  the  mechanism  required  for  the  in- 
duction of virus-associated  cell membrane  antigen(s).  It  may be  noted  also 
that the noninfectious particles are also deficient with regard to at least one 
other property that  is  a  regular  feature of C-type viruses:  they contain no 
reverse transcriptase (19). 
It  can therefore be stated that  (a)  MSV-transformed cells do not carry a 
sui  generis  virus-specific membrane  antigen;  the  presence of  an  MLV-type 
surface antigen signals infection with leukemia virus.  (b) Surface changes de- 350  CELLS  TRANSYORMED  BY  MURINE  SARCOMA  VIRUS 
tectable as antigens do not necessarily have to accompany viral oncogenesis in 
all its forms. 
Tumor-specific  transplantation  antigens  (TSTA)  or,  more  appropriately, 
tumor-associated  transplantation  antigens  (TATA),  have  been  found  in  all 
virus-induced  tumors  that  have  been  studied  previously  (20-22).  They are 
group specific in the sense that the same or overlapping antigenic specifieities 
can be demonstrated in all tumors induced by the same virus, even if they arise 
in different tissues  and different species, but  are different in tumors induced 
by unrelated viruses. In view of the fact that such antigens, e.g. the polyoma- 
associated TSTA, were resistant to prolonged negative selection against anti- 
genic cells by passage in preimmunized host (23), together with the fact that 
their  presence  (and  the  presence  of  other  vitally  induced  transplantation 
antigens as well) was regularly associated with neoplastic transformation, it was 
speculated  (20,  21,  24)  that  the  rearrangement  of  the  outer  cell membrane 
reflected in the appearance of the new antigens may represent the key change 
that makes  the cell disobedient to growth  control, i.e., neoplastic. This idea 
was  particularly  attractive  as  far  as  the  small  oncogenic DNA  viruses  are 
concerned, in view of their very limited amount of genetic information. 
The absence of any detectable virally associated surface antigen on MSV- 
transformed cells in  the present study,  together with  the lack of any trans- 
plantation antigen in the experiments of Stephenson and Aaronson (17)  raises 
doubts about the validity of this theory, or at least its general  applicability 
to  all  virus-induced systems.  Conceivably, MSV-indnced  cell transformation 
may still be accompanied by important membrane changes that are not recog- 
nized by the animal as new, foreign antigens, or not sufficiently to be detected 
by the  methods  used.  Alternatively,  neoplastic  growth  may not  be  due,  in 
this case at least,  to changes at the level of growth-regulating membrane re- 
ceptors, but may reside at some more central level within the cells. 
In addition to the MSV system, TSTA-like antigens were also undetectable 
on a minority of chemically induced tumors in the rat (25).  Moreover, hybrid 
cell lines derived from the fusion of polyoma virus-induced  mouse tumor cells 
and mouse L  cells  (A9  subline)  that  showed  a  suppression of malignant  be- 
havior still  carried the polyoma transplantation  antigen  (26), indicating that 
the presence of the antigen is not sufficient for the expression  of a malignant 
potential. In the C-type leukemia virus systems, the virally determined surface 
antigen,  carried by the leukemic cells,  can also be demonstrated,  apparently 
with  the  same  specificity, on  functionally unaffected  lymphocytes in  virus- 
infected hosts  (27)  or in  apparently unaltered  normal  bone  marrow-derived 
culture lines exposed to the leukemia virus (28). 
SUMMARY 
Some  nmrine  sarcoma  virus  (MSV)-transformed  mouse  3T3  cells  contain 
the  MSV  genome in  the  absence of infectious helper murine leukemia virus 
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These  cells,  designated  S+L-  (sarcoma  positive,  leukemia  negative), 
were analyzed for the presence of a possible MSV-determined membrane anti- 
gen  by  the  mixed  hemadsorption  test  and  in  vitro  lymphocyte cytotoxicity 
assay.  Two  different  serological  approaches  were  used:  (a)isoantibody-free 
sera were obtained by immunizing with MSV of syngeneic origin or by allow- 
ing primary, autologous MSV sarcomas to regress, or (b)  alloantisera obtained 
by immunizing C57BL mice with S+L--  cells were absorbed  with  the  corre- 
sponding  nontransformed  3T3  cells  until  all  activity  against  3T3  had  been 
removed. 
While MuLV-superinfected  S+L--  cells  and  a  culture line of an MSV sar- 
coma known  to produce  both  MSV  and  MLV  were  highly reactive,  normal 
3T3  and S+L--  cells were negative.  Similarly,  lymph node cells from  MSV 
immune mice or rats  did not kill  S+L--  cells,  although they were cytotoxic 
against  target  cells  known  to  carry  MuLV-associated  antigens.  Thus,  the 
present study gives no positive evidence for the existence of any MSV-induced 
new  surface  antigen  in the  transformed  target  cell,  known to carry the viral 
genome. 
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